These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 27432076)

  • 41. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Lipid therapy in patients with diabetes].
    Saely CH; Drexel H
    Wien Med Wochenschr; 2010 Jan; 160(1-2):25-9. PubMed ID: 20229158
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The lipid triad, or how to reduce residual cardiovascular risk?
    Girard-Mauduit S
    Ann Endocrinol (Paris); 2010 Mar; 71(2):89-94. PubMed ID: 20303470
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Dyslipidemias : Diagnostics and management].
    Sinning D; Landmesser U
    Herz; 2017 Sep; 42(6):607-620. PubMed ID: 28791432
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of Ezetimibe Alone or in Addition to a Statin on Plasma PCSK9 Concentrations in Patients with Type 2 Diabetes and Hypercholesterolemia: A Pilot Study.
    Miyoshi T; Nakamura K; Doi M; Ito H
    Am J Cardiovasc Drugs; 2015 Jun; 15(3):213-9. PubMed ID: 25896669
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease.
    Gebauer K; Reinecke H
    Vasa; 2018 Apr; 47(3):165-176. PubMed ID: 29412075
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes.
    Matikainen N; Taskinen MR
    Curr Cardiol Rep; 2012 Dec; 14(6):721-31. PubMed ID: 22941588
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Therapeutic targets in the treatment of dyslipidemia: HDL and non-HDL cholesterol].
    Brea Hernando ÁJ
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():3-6. PubMed ID: 25043539
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical trials of eicosapentaenoic acid (EPA) prescription products for the treatment of hypertriglyceridemia.
    Doggrell SA
    Expert Opin Pharmacother; 2019 Jul; 20(10):1221-1225. PubMed ID: 31038369
    [No Abstract]   [Full Text] [Related]  

  • 50. Management of dyslipidaemias in the elderly population-A narrative review.
    Anagnostis P; Vaitsi K; Veneti S; Georgiou T; Paschou SA; Lambrinoudaki I; Goulis DG
    Maturitas; 2019 Jun; 124():93-99. PubMed ID: 30910278
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Management of dyslipidemia in diabetes.
    Solano MP; Goldberg RB
    Cardiol Rev; 2006; 14(3):125-35. PubMed ID: 16628021
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
    Jacobson TA
    Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient.
    Watts GF; Karpe F
    Heart; 2011 Mar; 97(5):350-6. PubMed ID: 21296781
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role for combination therapy in diabetic dyslipidemia.
    Warraich HJ; Wong ND; Rana JS
    Curr Cardiol Rep; 2015 May; 17(5):32. PubMed ID: 25894802
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Best practice for treating dyslipidaemia in patients with diabetes based on current international guidelines.
    Lan NSR; Burns K; Bell DA; Watts GF
    Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):104-113. PubMed ID: 33278128
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
    Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy.
    Aguiar C; Alegria E; Bonadonna RC; Catapano AL; Cosentino F; Elisaf M; Farnier M; Ferrières J; Filardi PP; Hancu N; Kayikcioglu M; Mello E Silva A; Millan J; Reiner Ž; Tokgozoglu L; Valensi P; Viigimaa M; Vrablik M; Zambon A; Zamorano JL; Ferrari R
    Atheroscler Suppl; 2015 Sep; 19():1-12. PubMed ID: 26315511
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".
    Kohli P; Ganz P; Ma Y; Scherzer R; Hur S; Weigel B; Grunfeld C; Deeks S; Wasserman S; Scott R; Hsue PY
    J Am Heart Assoc; 2016 Apr; 5(5):. PubMed ID: 27130349
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.